None of the information provided is investment or tax advice.
You should always read the associated risks before deciding whether to invest. These can be found on the product pages as well as in our risks overview.
Please confirm you have read the information above.


Welcome to Downing LLP


Request information for

Product Offer Hero Title

Hello, thanks for your interest in investing with Downing. Please complete this form to receive the requested information.

Did you know. Risk warning. Take 2 mins to learn more.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
plus icon
document search icon 3
min read

Downing’s Ventures division to focus on Healthcare in strategic move

No items found.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.


  • asd
  • asd
  1. asdasd
  2. asd
  1. asd


Investment manager Downing LLP (Downing) has decided to focus all of its ventures activities in the growing healthcare sector, building on its expertise in this area and responding to interest from investors.

To facilitate this strategic move, the company has exchanged contracts to sell its non-healthcare ventures investment business to Foresight Group Holdings Ltd (Foresight). The sale includes the transfer of the investment management contracts for Downing Ventures EIS, Downing ONE VCT plc and Downing FOUR VCT plc - except the latter’s Healthcare share class - and is expected to complete later this month.

Downing will now concentrate all of its VCT and EIS activities in healthcare ventures, retaining the management of the Healthcare share class of Downing FOUR VCT plc, as well as its Healthcare EIS Knowledge Intensive Fund.

Downing’s non-healthcare ventures investment team will transfer to Foresight, providing continuity in the investment management of the non-healthcare EIS and VCT portfolios. And to help to ensure a smooth transition for investors and advisers in the transferring VCT and EIS products, Downing will continue to provide administration services and support to Foresight for a transitional period.

Tony McGing, CEO of Downing LLP, said:

“We are focusing our ventures investment strategy on the healthcare sector, where we are building on the excellent track record of our industry-leading healthcare ventures team and plan to continue to grow our VCT and EIS funds, alongside raising dedicated capital from institutional investors.

The UK excels in the healthcare sector and we believe it offers attractive growth opportunities on the back of accelerated medical advances and investor interest due to the Covid-19 pandemic.

This strategic move to focus on healthcare is also in line with Downing’s continuing emphasis on ESG and sustainability, as we look to invest into businesses that can deliver excellent returns to investors at the same time as making a positive impact.

For VCT and EIS investors, there will be continuity in the management and administration of the transferring funds. Foresight is an experienced VCT and EIS manager, with the scale and expertise to fund and support the future growth of the businesses in the transferring VCT and EIS portfolios.”

Read the RNS announcements from Downing ONE VCT plc and Downing FOUR VCT plc.


We're here to help

If you are a financial adviser, or discretionary fund manager call 020 7630 3319 or email us at

If you are a private investor call  020 7416 7780 or email